Edition:
United States

Navidea Biopharmaceuticals Inc (NAVB.A)

NAVB.A on American Stock Exchange

0.45USD
4:02pm EDT
Change (% chg)

$-0.01 (-1.30%)
Prev Close
$0.46
Open
$0.45
Day's High
$0.46
Day's Low
$0.45
Volume
17,754
Avg. Vol
86,343
52-wk High
$1.14
52-wk Low
$0.26

Latest Key Developments (Source: Significant Developments)

Navidea Biopharmaceuticals says on May 12, co got a ruling in favor of Ricardo Gonzalez finding that he was terminated by co without cause - SEC Filing
Tuesday, 16 May 2017 04:56pm EDT 

May 16 (Reuters) - Navidea Biopharmaceuticals Inc :Navidea Biopharmaceuticals - On May 12, co got a ruling in favor of Ricardo J. Gonzalez finding that he was terminated by co without cause - SEC Filing.Navidea - Gonzalez was awarded severance, bonus and benefits of $517,978 plus statutory interest from April 7, 2016, attorneys' fees.  Full Article

Navidea Biopharmaceuticals reports Q1 earnings $0.53/shr
Tuesday, 9 May 2017 04:15pm EDT 

May 9 (Reuters) - Navidea Biopharmaceuticals Inc :Navidea Biopharmaceuticals reports first quarter 2017 financial results.Q1 revenue $580,000 versus $948,000.Q1 earnings per share $0.53.  Full Article

Navidea Q4 loss per share $0.02
Wednesday, 29 Mar 2017 04:05pm EDT 

Navidea Biopharmaceuticals Inc : Navidea provides corporate update and reports full year 2016 results . Q4 loss per share $0.02 .Q4 revenue $3.4 million versus $4.3 million.  Full Article

Cardinal Health reports 5.8 pct passive stake in Navidea Biopharma
Monday, 13 Mar 2017 04:03pm EDT 

Cardinal Health Inc :Cardinal Health, Inc reports 5.8 percent passive stake in navidea biopharmaceuticals inc as of March 3, 2017 - sec filing.  Full Article

Navidea Biopharmaceuticals says reaches settlement with CRG relating to loan agreement
Thursday, 23 Feb 2017 10:32am EST 

Navidea Biopharmaceuticals Inc : Navidea Biopharmaceuticals - On Feb 22, 2017, Co, CRG, and Cardinal Health 414 read into record a settlement in interpleader action pending in Ohio . Navidea Biopharmaceuticals Inc - Parties agreed that CRG will be paid $59 million - SEC filing . Navidea Biopharmaceuticals - Co, CRG agreed that the $2 million currently being held in escrow pursuant to court order in the Ohio case - SEC filing . Navidea Biopharmaceuticals Inc - Cardinal Health 414 will post a $7 million letter of credit in favor of CRG .Navidea Biopharmaceuticals - Co, CRG agreed $3 million currently being held in escrow pursuant to court order in Texas case to be released to co at closing of deal.  Full Article

Navidea enters into letter of intent with cardinal health for sale of Lymphoseek in North America
Tuesday, 6 Sep 2016 06:59am EDT 

Navidea Biopharmaceuticals Inc: Navidea Biopharmaceuticals enters into letter of intent with cardinal health for the sale of Lymphoseek® in North America . Total consideration to Navidea would be capped at $310 million. . Navidea retains rights to non-competitive diagnostic indications and all therapeutic applications .Navidea would receive $80 million at closing, with future consideration tied to annual sales of Lymphoseek, certain milestones.  Full Article

Navidea Biopharmaceuticals says files for non-timely 10-Q
Wednesday, 10 Aug 2016 03:46pm EDT 

Navidea Biopharmaceuticals Inc : Says files for non-timely 10-Q - SEC Filing . Says company is still in the process of gathering certain required documentation Source - http://bit.ly/2aMWOmN Further company coverage: [NAVB.A] ((Bangalore.newsroom@thomsonreuters.com;)).  Full Article

Navidea Biopharmaceuticals Q2 loss per share $0.04
Thursday, 4 Aug 2016 06:59am EDT 

Navidea Biopharmaceuticals Inc : Navidea reports second quarter 2016 financial results . Q2 revenue $5.4 million . Q2 loss per share $0.04 . Continuing to explore alternative financing arrangements in order to refinance crg debt ."believes that actions of CRG are a violation of loan agreement and, as a result, CRG is in breach of loan agreement".  Full Article

Navidea gets IRB nod for Lymphoseek rheumatoid arthritis trial protocol
Tuesday, 19 Jul 2016 06:59am EDT 

Navidea Biopharmaceuticals Inc : Navidea receives IRB approval for its Lymphoseek rheumatoid arthritis clinical trial protocol . Study will begin enrolling patients shortly .Navidea has received WIRB IRB approval to expand this study to other study sites at Navidea's discretion.  Full Article

Navidea Biopharma says continuing to explore alternative financing to refinance some debt
Thursday, 2 Jun 2016 05:55pm EDT 

Navidea Biopharmaceuticals Inc : Received letter dated May 31, 2016 from Capital Royalty Partners II L.P and Capital Royalty Partners II Parallel Fund A L.P. (CRG) . Company is continuing to explore alternative financing arrangements in order to refinance some debt - SEC filing . Company disputes amounts claimed to be due and believes that CRG does not have right to accelerate loan . "Believes that actions of CRG are violation of loan agreement and, as a result, CRG is in breach of loan agreement, not co" . Reiterates its firmly held position that alleged claims do not constitute events of default under loan agreement . "Company believes that its best course of action is to refinance CRG debt and pursue its claims for damages" . CRG declared all of co's obligations under loan agreement,all other loan documents to be immediately due and payable in amount of $56.1 million . Reiterates position that alleged claims do not constitute events of default under loan agreement ."Company is working on preparation of counterclaims which it expects to assert".  Full Article

More From Around the Web